Company intelligence / Profile preview

Allkem

Mumbai, Maharashtra, India

Ownership: Private
Development stage: Other

Overview

Alkem Laboratories operates primarily in the commercial stage with approved products including olanzapine for schizophrenia, dronabinol for nausea, and evogliptin for type 2 diabetes. The company has early-stage pipeline programs including a denosumab biosimilar and atexakin alfa for diabetic peripheral neuropathy, both in Phase 1.

Therapeutic areas: GastroenterologyEndocrinologyPsychiatry
Modalities: Small moleculeBiosimilarMonoclonal antibodyInterleukins
Industry: Biotech

Beyond the preview

Go deeper on Allkem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allkem.

Explore the full profile